Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) on Monday, plunged -42.32% from the previous trading day, before settling in for the closing price of $34.19. Within the past 52 weeks, RARE’s price has moved between $25.81 and $46.50.
During the last 5-year period, the sales growth of Healthcare Sector giant was 2.45%. The company achieved an average annual earnings per share of 10.21%. With a float of $89.77 million, this company’s outstanding shares have now reached $96.27 million.
Ultragenyx Pharmaceutical Inc (RARE) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Ultragenyx Pharmaceutical Inc is 6.95%, while institutional ownership is 99.09%. The most recent insider transaction that took place on Dec 10 ’25, was worth 112,087. In this transaction Chief Financial Officer of this company sold 3,081 shares at a rate of $36.38, taking the stock ownership to the 95,146 shares. Before that another transaction happened on Dec 10 ’25, when Company’s Officer proposed sale 3,081 for $36.38, making the entire transaction worth $112,087.
Ultragenyx Pharmaceutical Inc (RARE) Recent Fiscal highlights
As on 12/31/2024, Multinational firm has announced its last quarter scores, in which it reported -1.39 earnings per share (EPS) for the period falling under the consensus outlook (set at -1.27) by -0.12. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.47 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 10.21% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 38.19% during the next five years compared to 2.45% growth over the previous five years of trading.
Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) Trading Performance Indicators
Ultragenyx Pharmaceutical Inc (RARE) is currently performing well based on its current performance indicators. A quick ratio of 1.74 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.02.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.94, a number that is poised to hit -1.17 in the next quarter and is forecasted to reach -4.18 in one year’s time.
Technical Analysis of Ultragenyx Pharmaceutical Inc (RARE)
Looking closely at Ultragenyx Pharmaceutical Inc (NASDAQ: RARE), its last 5-days average volume was 5.25 million, which is a jump from its year-to-date volume of 1.45 million. As of the previous 9 days, the stock’s Stochastic %D was 30.30%.
During the past 100 days, Ultragenyx Pharmaceutical Inc’s (RARE) raw stochastic average was set at 6.10%, which indicates a significant decrease from 7.12% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.24 in the past 14 days, which was lower than the 1.27 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $33.63, while its 200-day Moving Average is $33.39. However, in the short run, Ultragenyx Pharmaceutical Inc’s stock first resistance to watch stands at $20.67. Second resistance stands at $21.62. The third major resistance level sits at $22.75. If the price goes on to break the first support level at $18.59, it is likely to go to the next support level at $17.46. Now, if the price goes above the second support level, the third support stands at $16.51.
Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) Key Stats
Market capitalization of the company is 1.90 billion based on 96,478K outstanding shares. Right now, sales total 560,230 K and income totals -569,180 K. The company made 159,930 K in profit during its latest quarter, and -180,410 K in sales during its previous quarter.
